Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease.
| INTRODUCTION
Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease.
1 CD30+
LPDs comprise approximately 25%-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T-cell neoplasm of the skin behind mycosis fungoides (MF). 2-6 Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis (LyP), and more aggressive hematolymphoid neoplasms.
| CLINICAL PRESENTATION AND PROGNOSIS
PC-ALCL classically presents as solitary, grouped or multifocal nodules on the upper half of the body that persist for at least 3 to 4 weeks. [7] [8] [9] Most patients are 50 to 70 years in age but pediatric and congenital cases have been described. 10,11 PC-ALCL not infrequently shows spontaneous regression (20%-42% of cases), but up to half of cases can recur. 1, 8, [11] [12] [13] [14] Five-year survival for early stage PC-ALCL ranges between 90% and 97.5% for T1 disease, 93% for T1
and T2 combined and 77% for T3. 8, 12, [15] [16] [17] Extra cutaneous spread occurs in 10% of cases and is most likely to involve regional lymph nodes. Spontaneous regression and age under 60 are favorable prognostic indicators, while extensive limb disease (ELD), extracutaneous disease, and age over 60 are unfavorable. 18 With ELD, 5-year survival drops to 50%. 19 Leg involvement confers a worse prognosis regardless of T category (76% 5-year disease specific survival for leg involvement compared with 96% for patients without leg involvement). Several studies have showed similarly poor outcomes for leg/limb involvement of PC-ALCL, with an associated higher likelihood of extensive and multiple skin lesions as well as regional nodal involvement. [20] [21] [22] Overall extent of skin lesions independently correlates with worse prognosis. 22 Initial involvement of the head and neck has been reported to confer a worse prognosis, although this is not a consistent finding in the literature. 23, 24 Involvement of muscle or deep fascia or other deep tissues may also confer a worse prognosis. 25 Patients may present with isolated intralymphatic involvement;
however, the prognostic implications of this finding are not clear. 26, 27 Posttherapy relapses are most likely to be restricted to the skin; however, extracutaneous involvement has been reported in up to 27% of relapses, with half of those cases representing local nodal involvement. 17 , 28 Visceral metastasis have been documented to occur between 2 months to 10 years from initial diagnosis. 17 The development of metastatic disease is not always associated with progression to a higher T category, however. CD45 is positive in most PC-ALCL and negative in NSCHL, potentially serving as a useful marker for this differential. 64 Leukemia cutis can also show similar histology to PC-ALCL but usually expresses immature hematolymphoid markers such as TdT, CD34 and/or CD117 and myeloid lineage markers such as myeloperoxidase.
| ETIOLOGY AND PATHOGENESIS
CD30+ blasts are present in normal lymphoid tissue in a small percentage, with perifollicular and to a lesser extent, intrasinusoidal localization. 39 This cell is the proposed precursor cell to S-ALCL, but the precursor of PC-ALCL is not characterized. 39 CD30+ T cells can be seen in a wide range of reactive entities including arthropod bite reactions, eczema and dermatopathic lymphadenopathy. 65 Interaction between CD30 and its ligand (CD30L) is thought to mediate proliferative and antiproliferative stages of disease. 66 In a study of regressing and growing lesions from patients with CD30+ LPD, Mori et al 66 found that the expression of CD30L was greater in regressing lesions, supporting the antiproliferative effects of the CD30-CD30L 124 Low or absent BCL2 expression appears to be a common feature in PC-ALCL, and BCL2 copy number loss can be seen.
90
MicroRNAs (miRNAs) are small non-coding RNAs that posttranscriptionally regulate gene expression. 125 Benner et al. 125 found 13 differentially expressed miRNAs in PC-ALCL compared to benign inflammatory conditions. Furthermore, a subset of miRNAs were differentially expressed in PC-ALCL and tumor stage MF when using quantitative PCR instead of microarray analysis. 125 Differences in miRNA expression between MF and PC-ALCL have been supported by other studies and suggests that these differences may someday provide additional diagnostically useful information. 126 While not in routine clinical practice, there is some data suggesting that telomere length is different in PC-ALCL compared with MF and Szary syndrome. Chevret et al. 127 looked at telomere length and telomerase activity in primary cutaneous TCL and found that while in PC-ALCL telomere length was similar to control lymphocytes, telomerase activity was detected in the majority of PC-ALCL cases and not in controls. In addition, the investigators found that telomere length was shorter in MF and Sézary syndrome, compared to PC-ALCL. 
| CONCLUSIONS

